Lycopene corrects metabolic syndrome and liver injury induced by high fat diet in obese rats through antioxidant, anti-inflammatory, antifibrotic pathways

Biomed Pharmacother. 2021 Jul 5;141:111831. doi: 10.1016/j.biopha.2021.111831. Online ahead of print.ABSTRACTObesity is a global epidemic disease that is closely associated with various health problems as Diabetes mellitus, cardiovascular, and metabolic disorders. Lycopene (LYC), a red-colored carotenoid, has demonstrated various promising therapeutic effects. Hence, the potential of LYC was studied against high fat diet (HFD)-induced obesity and metabolic disturbances in rats. Animals fed on HFD and orally supplemented with LYC (25 and 50 mg/kg) or simvastatin (10 mg/kg) every day for 3 months. The results revealed that long-term consumption of HFD significantly increased weight gain, liver weight, cholesterol, triglycerides (TG), apolipoprotein-B (Apo-B), low-density lipoprotein-cholesterol (LDL-c) levels, as well as decreasing the high-density lipoprotein-cholesterol (HDL-c) levels. Moreover, high blood glucose and insulin levels accompanied by low peroxisome proliferator activated receptor gamma (PPAR-γ) were recorded in HFD group. Further, HFD rats displayed lower levels of antioxidant biomarkers (SOD, CAT, GPx, GR and GSH), in addition to higher levels of MDA, NO and inflammatory mediators (IL-1β, TNF-α, and MPO). Marked increases were observed in atherogenic index, lactate dehydrogenase and creatine kinase together with fibrosis markers (TGF-β1 and α-SMA) in rats fed on HFD. Comparing to model group, LYC was able to effectively reverse HFD-m...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

AbstractAims/hypothesisThe aim of this study was to investigate the concordance of dysglycaemia (prediabetes or diabetes) and cardiometabolic traits between women with a history of gestational diabetes mellitus (GDM) and their spouses.MethodsUsing hospital medical records, women with GDM (diagnosed between 2012 and 2016) and their spouses were invited to participate in the study and to attend a scheduled hospital visit in a fasting state. Sociodemographic, anthropometric and medical data were collected, and a 75  g OGTT with serum insulin estimation, HbA1c measurement and fasting lipid profile were performed at the vi...
Source: Diabetologia - Category: Endocrinology Source Type: research
In conclusion, the impaired in situ activity of RyR2 may also account for the poor overall cardiac outcome reported in MetS patients; hence, the SERCA pump and RyR2 are both attractive potential targets for future therapies. Introduction Metabolic syndrome (MetS) is a cluster of biochemical and physiological risk factors for cardiovascular disease and diabetes mellitus type 2 (DM2); it represents a severe public health problem around the world (Alberti et al., 2009). Risk factors for MetS include obesity (particularly central obesity), elevated triglyceride (TG) levels, low high-density lipoprotein cholesterol (HDL...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Mildren Porchas-Quijada1, Zyanya Reyes-Castillo1*, José Francisco Muñoz-Valle2, Sergio Durán-Barragán3,4, Virginia Aguilera-Cervantes1, Antonio López-Espinoza1, Mónica Vázquez-Del Mercado4, Mónica Navarro-Meza1 and Patricia López-Uriarte1 1Instituto de Investigaciones en Comportamiento Alimentario y Nutrición, Centro Universitario del Sur, Universidad de Guadalajara, Ciudad Guzmán, Mexico 2Instituto de Investigaciones en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexic...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Dan Hu1†, Meijin Zhang2†, Hejun Zhang1, Yan Xia1, Jinxiu Lin2, Xiongwei Zheng1, Feng Peng2* and Wenquan Niu3* 1Department of Pathology, Fujian Cancer Hospital &Fujian Medical University Cancer Hospital, Fuzhou, China 2Department of Cardiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China 3Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China Background and Objectives: Growing evidence indicates that metabolic syndrome confers a differential risk for the development and progression of many types of cancer, especially in the digestive tr...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Shafqat Ahmad1,2,3*, Syeda Sadia Fatima4, Gull Rukh5 and Caren E. Smith6 1Department of Medical Sciences, Molecular Epidemiology, Uppsala University, Uppsala, Sweden 2Preventive Medicine Division, Harvard Medical School, Brigham and Women's Hospital, Boston, MA, United States 3Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, United States 4Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan 5Department of Neuroscience, Functional Pharmacology, Uppsala University, Uppsala, Sweden 6Nutrition and Genomics Laboratory, Jean Mayer U. S. Depa...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Metabolic syndrome (MS) is a constellation of risk factors, which, when not treated, leads to the development of type 2 diabetes mellitus (T2DM) and coronary heart disease (CHD). It is a prevalent condition, which is associated with the growing epidemic of sedentary lifestyle[1]. MS is diagnosed when at least three out of five following risk factors are present: central obesity, elevated serum triglycerides, low HDL cholesterol concentrations, impaired fasting glucose and elevated systolic (SBP) or/and diastolic blood pressure (DBP)[2].
Source: Maturitas - Category: Primary Care Authors: Source Type: research
Overweight and obesity is epidemic across the developed world and prevalence in Australia is amongst the highest, with obesity alone costing the health system an estimated $837million[1]. Approximately 40% of Australians are overweight, undoubtedly adding to these costs and burden on the healthcare system[1]. Obesity and overweight comprise some of the key features of the Metabolic Syndrome (MetS), which is defined as central obesity plus any two of the following: raised triglycerides>1.7mmol/L, decreased high density lipoprotein cholesterol (HDL)5.6mmol/L or diagnosis of type 2 diabetes mellitus (T2DM).
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Tags: Review Source Type: research
Conclusion Vitamin D, family history of diabetes, consanguinity marriages’ and hereditary gene-environment interactions and physical exercise may also contribute to the current diabetes epidemic in Qatari’s Arab populations.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Conclusion Prevention is better than cure. The need of the hour is to target premenopausal women who are at risk of developing MetS in their postmenopausal age. It will delay and prevent them from future morbidities.
Source: The Journal of Obstetrics and Gynecology of India - Category: OBGYN Source Type: research
Over the past two decades, I have watched with increasing alarm the skyrocketing numbers of patients with type 2 diabetes who come to my wellness clinic. Often, they come to see me about other medical issues, but their diabetes adds a new level of complications to their treatment. Type 2 diabetes occurs when the body’s response to insulin – the hormone critical for the maintenance of healthy blood sugar levels – becomes either ineffective or the insulin itself is produced in insufficient amounts. The horrific trend I’m seeing at my wellness clinic mirrors almost exactly what’s happening in the...
Source: Al Sears, MD Natural Remedies - Category: Complementary Medicine Authors: Tags: Nutrition diabetes insulin statins type 2 diabetes Source Type: news
More News: Antidoxidants | Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Mellitus | Diets | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Epidemics | Epidemiology | Heart | High Fat | Insulin | Liver | Lycopene | Metabolic Syndrome | Nutrition | Obesity | Simvastatin | Statin Therapy | Urology & Nephrology | Zocor